TCL Archive FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI April 15, 1977
TCL Archive Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events June 28, 2013
TCL Archive FASEB Seeks $27.3B For NIH, Increases For Research, Training, And Infrastructure. February 1, 2002
